Cargando…

Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors

Peptidylarginine deiminase type 4 (PADI4) converts arginine residues into citrulline. The current study focused on the expression of PADI4 in various subtypes of ovary cancers, and this study investigated the effects of estrogen on PADI4 expression in SKOV-3 cells that originated from ovary tumors....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lin, Chang, Xiaotian, Yuan, Guangying, Zhao, Yan, Wang, Pengcheng
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935668/
https://www.ncbi.nlm.nih.gov/pubmed/20827398
_version_ 1782186419510312960
author Wang, Lin
Chang, Xiaotian
Yuan, Guangying
Zhao, Yan
Wang, Pengcheng
author_facet Wang, Lin
Chang, Xiaotian
Yuan, Guangying
Zhao, Yan
Wang, Pengcheng
author_sort Wang, Lin
collection PubMed
description Peptidylarginine deiminase type 4 (PADI4) converts arginine residues into citrulline. The current study focused on the expression of PADI4 in various subtypes of ovary cancers, and this study investigated the effects of estrogen on PADI4 expression in SKOV-3 cells that originated from ovary tumors. We utilized immunohistochemistry, real-time PCR and western blotting to analyze the expression of PADI4 in the tumor tissues and in the cell line that were cultured with estrodial-17β. PADI4 was detected in serious cystadenocarcinoma (n=39, positivity=100%), clear cell cancer (n=7, positivity= 100%), mucinous cystadenocarcinoma (n=6, positivity=100%), dysgerminoma (n=6, positivity=100%), squamous cell tumor (n=6, positivity=100%), sibnet-ring cell carcinoma (n=6, positivity=100%), endodermal sinus tumor (n=6, positivity=100%), germ cell tumors (n=6, positivity=100%) and immature teratoma (n=6, positivity=100%). However, PADI4 was either not detected or detected at low levels in granulosa cell tumor (n=6), malignant thecoma (n=6), ovarian cystadenoma (n=5) and normal ovarian tissue (n=11). For serious cystadenocarcinoma, all of the samples with high PADI4 expression belonged to the T1 and T2 stages of pTMN, whereas all of the samples that exhibited weak or moderate PADI4 expression belonged to the T3 and T4 stages. PADI4 was evenly distributed in the cytoplasm of tumor cells of serious cystadenocarcinoma that were classified as being grade II and III by histopathological scoring. However, PADI4 showed granular cellular distribution in the tumor tissues that were isolated from grade I cystadenocarcinoma. In addition, the PADI4 level was positively related with the ages of the patients that presented with serious adenocarcinoma (p=0.029). Real-time PCR and western blot analyses confirmed that PADI4 was expressed at higher levels in ovarian adenocarcinoma (n=8) compared to ovarian cystadenoma (n=5) (p< 0.05). The study also detected an increased level of PADI4 in SKOV-3 cells that were incubated with estrodial-17β in the range of 10(-12) to 10(-4)M. The results suggest an important role for PADI4 in the tumorigenesis of ovary cancers that are under the regulation of estrogen.
format Text
id pubmed-2935668
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-29356682010-09-08 Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors Wang, Lin Chang, Xiaotian Yuan, Guangying Zhao, Yan Wang, Pengcheng Int J Biol Sci Research Paper Peptidylarginine deiminase type 4 (PADI4) converts arginine residues into citrulline. The current study focused on the expression of PADI4 in various subtypes of ovary cancers, and this study investigated the effects of estrogen on PADI4 expression in SKOV-3 cells that originated from ovary tumors. We utilized immunohistochemistry, real-time PCR and western blotting to analyze the expression of PADI4 in the tumor tissues and in the cell line that were cultured with estrodial-17β. PADI4 was detected in serious cystadenocarcinoma (n=39, positivity=100%), clear cell cancer (n=7, positivity= 100%), mucinous cystadenocarcinoma (n=6, positivity=100%), dysgerminoma (n=6, positivity=100%), squamous cell tumor (n=6, positivity=100%), sibnet-ring cell carcinoma (n=6, positivity=100%), endodermal sinus tumor (n=6, positivity=100%), germ cell tumors (n=6, positivity=100%) and immature teratoma (n=6, positivity=100%). However, PADI4 was either not detected or detected at low levels in granulosa cell tumor (n=6), malignant thecoma (n=6), ovarian cystadenoma (n=5) and normal ovarian tissue (n=11). For serious cystadenocarcinoma, all of the samples with high PADI4 expression belonged to the T1 and T2 stages of pTMN, whereas all of the samples that exhibited weak or moderate PADI4 expression belonged to the T3 and T4 stages. PADI4 was evenly distributed in the cytoplasm of tumor cells of serious cystadenocarcinoma that were classified as being grade II and III by histopathological scoring. However, PADI4 showed granular cellular distribution in the tumor tissues that were isolated from grade I cystadenocarcinoma. In addition, the PADI4 level was positively related with the ages of the patients that presented with serious adenocarcinoma (p=0.029). Real-time PCR and western blot analyses confirmed that PADI4 was expressed at higher levels in ovarian adenocarcinoma (n=8) compared to ovarian cystadenoma (n=5) (p< 0.05). The study also detected an increased level of PADI4 in SKOV-3 cells that were incubated with estrodial-17β in the range of 10(-12) to 10(-4)M. The results suggest an important role for PADI4 in the tumorigenesis of ovary cancers that are under the regulation of estrogen. Ivyspring International Publisher 2010-08-27 /pmc/articles/PMC2935668/ /pubmed/20827398 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Research Paper
Wang, Lin
Chang, Xiaotian
Yuan, Guangying
Zhao, Yan
Wang, Pengcheng
Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors
title Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors
title_full Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors
title_fullStr Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors
title_full_unstemmed Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors
title_short Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors
title_sort expression of peptidylarginine deiminase type 4 in ovarian tumors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935668/
https://www.ncbi.nlm.nih.gov/pubmed/20827398
work_keys_str_mv AT wanglin expressionofpeptidylargininedeiminasetype4inovariantumors
AT changxiaotian expressionofpeptidylargininedeiminasetype4inovariantumors
AT yuanguangying expressionofpeptidylargininedeiminasetype4inovariantumors
AT zhaoyan expressionofpeptidylargininedeiminasetype4inovariantumors
AT wangpengcheng expressionofpeptidylargininedeiminasetype4inovariantumors